These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 29956805)

  • 1. Tumor‑penetrating peptide fused EGFR single‑domain antibody enhances radiation responses following EGFR inhibition in gastric cancer.
    Ji F; Sha H; Meng F; Zhu A; Ding N; Zhang H; Xu H; Qian H; Yu L; Liu Q; Liu B
    Oncol Rep; 2018 Sep; 40(3):1583-1591. PubMed ID: 29956805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [EGFR-blockade by antibody Cetuximab inhibits the growth of human gastric cancer xenograft in nude mice and its possible mechanism].
    Zhang J; Ji J; Yuan F; Ma T; Ye ZB; Yu YY; Liu BY; Zhu ZG
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):85-9. PubMed ID: 19538880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers.
    Li C; Huang S; Armstrong EA; Francis DM; Werner LR; Sliwkowski MX; van der Kogel A; Harari PM
    Mol Cancer Ther; 2015 Sep; 14(9):2049-59. PubMed ID: 26141946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer.
    Liu H; Lu J; Hua Y; Zhang P; Liang Z; Ruan L; Lian C; Shi H; Chen K; Tu Z
    Cell Death Dis; 2015 Jan; 6(1):e1595. PubMed ID: 25590805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers.
    Huang S; Peet CR; Saker J; Li C; Armstrong EA; Kragh M; Pedersen MW; Harari PM
    Mol Cancer Ther; 2013 Dec; 12(12):2772-81. PubMed ID: 24130052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation.
    Harari PM; Huang SM
    Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):427-33. PubMed ID: 11173137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models.
    Francis DM; Huang S; Armstrong EA; Werner LR; Hullett C; Li C; Morris ZS; Swick AD; Kragh M; Lantto J; Kimple RJ; Harari PM
    Clin Cancer Res; 2016 Feb; 22(3):633-43. PubMed ID: 26420857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nimotuzumab, an EGFR‑targeted antibody, promotes radiosensitivity of recurrent esophageal squamous cell carcinoma.
    Yu Y; Guan H; Jiang L; Li X; Xing L; Sun X
    Int J Oncol; 2020 Apr; 56(4):945-956. PubMed ID: 32319582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy.
    Sha H; Zou Z; Xin K; Bian X; Cai X; Lu W; Chen J; Chen G; Huang L; Blair AM; Cao P; Liu B
    J Control Release; 2015 Feb; 200():188-200. PubMed ID: 25553823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo.
    Mu Y; Sun D
    Med Sci Monit; 2018 Aug; 24():5811-5819. PubMed ID: 30125265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of gefitinib on radiosensitivity of gastric cancer cell lines].
    Cao WG; Ma T; Li JF; Li H; Ji YB; Chen XH; Liu BY; Jin YN
    Ai Zheng; 2007 Dec; 26(12):1330-5. PubMed ID: 18076795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coupling Gd‑DTPA with a bispecific, recombinant protein anti‑EGFR‑iRGD complex improves tumor targeting in MRI.
    Xin X; Sha H; Shen J; Zhang B; Zhu B; Liu B
    Oncol Rep; 2016 Jun; 35(6):3227-35. PubMed ID: 27035336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells.
    Tsai YC; Ho PY; Tzen KY; Tuan TF; Liu WL; Cheng AL; Pu YS; Cheng JC
    Mol Cancer Ther; 2015 Mar; 14(3):810-20. PubMed ID: 25589492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts.
    Sreeranganathan M; Uthaman S; Sarmento B; Mohan CG; Park IK; Jayakumar R
    Int J Nanomedicine; 2017; 12():7165-7182. PubMed ID: 29033568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3.
    Doyle HA; Koski RA; Bonafé N; Bruck RA; Tagliatela SM; Gee RJ; Mamula MJ
    Cancer Immunol Immunother; 2018 Oct; 67(10):1559-1569. PubMed ID: 30056598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumor-Initiating Cell Frequency.
    Fu W; Lei C; Yu Y; Liu S; Li T; Lin F; Fan X; Shen Y; Ding M; Tang Y; Ye X; Yang Y; Hu S
    Clin Cancer Res; 2019 May; 25(9):2835-2847. PubMed ID: 30670492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
    Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin.
    Stache C; Bils C; Fahlbusch R; Flitsch J; Buchfelder M; Stefanits H; Czech T; Gaipl U; Frey B; Buslei R; Hölsken A
    Neurosurg Focus; 2016 Dec; 41(6):E14. PubMed ID: 27903123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. β-elemene enhances the radiosensitivity of gastric cancer cells by inhibiting Pak1 activation.
    Liu JS; Che XM; Chang S; Qiu GL; He SC; Fan L; Zhao W; Zhang ZL; Wang SF
    World J Gastroenterol; 2015 Sep; 21(34):9945-56. PubMed ID: 26379399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.